Belumosudil, a specific inhibitor of ROCK2 [169], was recently approved by the FDA for the treatment of graft-versus-host-disease (GVHD), particularly its fibrotic component, after the failure of prior therapies [170,171]. The gene discussed is ROCK2; the disease is graft versus host disease.